Murthy, K. S., J. R. Grider, and G. M. Makhlouf. Heterologous desensitization of response mediated by selective PKC-dependent phosphorylation of G i-1 and G i-2 . Am J Physiol Cell Physiol 279: C925-C934, 2000.-This study examined the ability of protein kinase C (PKC) to induce heterologous desensitization by targeting specific G proteins and limiting their ability to transduce signals in smooth muscle. Activation of PKC by pretreatment of intestinal smooth muscle cells with phorbol 12-myristate 13-acetate, cholecystokinin octapeptide, or the phosphatase 1 and phosphatase 2A inhibitor, calyculin A, selectively phosphorylated G␣ i-1 and G␣ i-2 , but not G␣ i-3 or G␣ o , and blocked inhibition of adenylyl cyclase mediated by somatostatin receptors coupled to G i-1 and opioid receptors coupled to G i-2 , but not by muscarinic M 2 and adenosine A 1 receptors coupled to G i-3 . Phosphorylation of G␣ i-1 and G␣ i-2 and blockade of cyclase inhibition were reversed by calphostin C and bisindolylmaleimide, and additively by selective inhibitors of PKC␣ and PKCε. Blockade of inhibition was prevented by downregulation of PKC. Phosphorylation of G␣-subunits by PKC also affected responses mediated by ␤␥-subunits. Pretreatment of muscle cells with cANP-(4-23), a selective agonist of the natriuretic peptide clearance receptor, NPR-C, which activates phospholipase C (PLC)-␤3 via the ␤␥-subunits of G i-1 and G i-2 , inhibited the PLC-␤ response to somatostatin and [D-Pen 2,5 ]enkephalin. The inhibition was partly reversed by calphostin C. Short-term activation of PKC had no effect on receptor binding or effector enzyme (adenylyl cyclase or PLC-␤) activity. We conclude that selective phosphorylation of G␣ i-1 and G␣ i-2 by PKC partly accounts for heterologous desensitization of responses mediated by the ␣-and ␤␥-subunits of both G proteins. The desensitization reflects a decrease in reassociation and thus availability of heterotrimeric G proteins.
tors, G proteins, and/or effector enzymes. The strength and duration of the signal is determined by G proteinspecific GTPase-activating proteins known as "regulators of G protein signaling" (RGS) and by the intrinsic GTPase activities of the ␣-subunit and some effector enzymes [e.g., phospholipase C (PLC)-␤] (1, 2, 9). GTP hydrolysis promotes the reassociation of the ␣-and ␤␥-subunits that impede further activation of effector enzymes by ␣-or ␤␥-subunits.
Considerable attention has been devoted to mechanisms that induce short-term or long-term desensitization of receptors. Rapid homologous desensitization of agonist-occupied receptors is initiated by specific receptor protein kinases (G protein-coupled receptor kinases) and the binding of ␤-arrestins to the phosphorylated receptor, which uncouples the receptor from the G protein as a prelude to receptor endocytosis and recycling (3, 10, (35) (36) (37) . The process of desensitization may be complemented by feedback phosphorylation via second messenger-activated protein kinases, chiefly protein kinase C (PKC), and cAMP-and cGMP-dependent protein kinases (PKA and PKG). Phosphorylation by these kinases does not require receptor occupancy and can thus target both homologous and heterologous receptors (35, 37) . Phosphorylation of some receptors (e.g., ␤ 2 -adrenergic receptors by PKA) can alter the specificity of receptor coupling to G proteins and initiate a different signaling cascade (7) . Second messenger-activated kinases can induce desensitization also by targeting effector enzymes and attenuating their activity [e.g., phosphorylation of PLC-␤ (12, 18, 39) and phospholipase A 2 (28) by PKG and PKA, and adenylyl cyclase type II by PKC] (41, 43, 46) .
Phosphorylation of the ␣-or ␤-subunits of some G proteins has been proposed as a mechanism of desensitization that targets G proteins and limits their ability to transduce signals (11, 15, 16, (19) (20) (21) (22) 45) . PKCdependent phosphorylation of G␣ z and G␣ 12 has been demonstrated (11, 16) , but evidence for phosphorylation of other G proteins, including various isoforms of G i , has been conflicting (4-6, 16, 22, 40) . Phosphorylation of G␣ z and G␣ 12 appears to decrease the affinity of G␣ for G␤␥, impeding reassociation of the subunits and decreasing the availability of the heterotrimeric G protein in the plasma membrane. The present study examined whether G i-1 , G i-2 , G i-3 , and G o were targets of phosphorylation by PKC in intestinal smooth muscle, and whether phosphorylation of one or more of these G proteins resulted in heterologous desensitization. The results indicate that G i-1 and G i-2 , but not G i-3 or G o , are phosphorylated by PKC, resulting in attenuation of subsequent responses mediated by both G proteins.
MATERIALS AND METHODS
Preparation of dispersed smooth muscle cells. Smooth muscle cells were isolated from the circular muscle layer of rabbit intestine by sequential enzymatic digestion, filtration, and centrifugation as described previously (23) (24) (25) (26) . Muscle strips were incubated for 30 min at 31°C in 15 ml of HEPES medium containing 0.1% collagenase and 0.1% soybean trypsin inhibitor. The partly digested strips were washed with 100 ml of enzyme-free medium, and the muscle cells were allowed to disperse spontaneously for 30-60 min. The cells were harvested by filtration through a 500-m Nitex mesh followed by two 10-min centrifugations at 350 g.
Measurement of cAMP in dispersed smooth muscle cells. cAMP was measured in dispersed cells by radioimmunoassay as described previously (23, 24, 26) . Aliquots (0.5 ml) containing 10 6 cells/ml were incubated with various agents, and the reaction was terminated after 60 s with 60% cold trichloroacetic acid (vol/vol). The mixture was centrifuged at 2,000 g for 15 min at 4°C. The supernatant was extracted three times with 2 ml of diethyl ether and lyophilized. The samples were reconstituted for radioimmunoassay in 500 l of 50 mM sodium acetate (pH 6.2) and acetylated with triethylamine/ acetic anhydride (2:1 vol/vol) for 30 min. cAMP was measured in duplicate with the use of 100-l aliquots and expressed as pmol/10 6 cells. Measurement of adenylyl cyclase activity in muscle membranes. Smooth muscle cells were incubated with phorbol 12-myristate 13-acetate (PMA, 1 M) for 10 min, and a crude homogenate was prepared in 50 mM Tris ⅐ HCl (pH 7.4), 1 mM ATP, 2 mM cAMP, 100 M isobutyl methyl xanthine, 5 mM MgCl 2 , 100 mM NaCl, 5 mM creatine phosphate, and 50 U/ml creatine kinase. Adenylyl cyclase activity was measured in the presence of [ 32 P]ATP and 1 mM GTP by an adaptation of the method of Salomon et al. (38) . The reaction was terminated after 15 min by addition of stop solution containing 2% SDS, 45 mM ATP, and 1.5 mM cAMP. [ 32 P]cAMP was separated by sequential chromatography on Dowex AG50W-4X and alumina columns. The samples were measured by scintillation counting, and the results were expressed as picomoles of cAMP per milligram of protein per minute.
Measurement of inositol phosphates. Total inositol phosphate formation in smooth muscle cells was measured by ion-exchange chromatography as described previously (31) . Ten milliliters of cell suspension (2ϫ 10 6 cells/ml) were labeled with myo- [ 3 H]inositol (15 Ci/ml) for 3 h at 31°C. After centrifugation at 350 g for 10 min, the cells were resuspended in 10 ml of fresh HEPES medium. After treatment with a cANP-(4-23) for 10 min, the cells were centrifuged at 350 g for 5 min. [D-Pen 2, 5 ]enkephalin (DPDPE), somatostatin, or cyclopentyladenosine (CPA) was then added to 0.5 ml of cell suspension and the samples incubated for 30 s. The reaction was terminated with 940 l of chloroform:methanol:HCl (50: 100:1, vol/vol/vol). After addition of chloroform (310 l) and water (310 l), the samples were vortexed, and the phases were separated by centrifugation at 1,000 g for 15 min. The upper aqueous phase was applied to a column that contained 1 ml of 1:1 slurry of Dowex AG1-X8 resin (100-200 mesh in formate form) and distilled water. The column was washed with 10 ml of water followed by 10 ml of 5 mM sodium tetraborate-60 mM ammonium formate. Inositol phosphates were eluted with 5 ml of 0.8 M ammonium formate-0.1 M formic acid. The eluates were collected into scintillation vials and counted in gel phase after addition of 10 ml of scintillant. The results were expressed as counts per minute (cpm)/10 6 cells or percentage increase above basal levels.
Immunoblotting of 32 P-labeled G␣ subunits. Ten milliliters of smooth muscle cell suspension (2-3 ϫ 10 6 cells/ml) were incubated with [ 32 P]orthophosphate for 4 h at 31°C. Onemilliliter samples were then incubated with PMA for 10 min and microfuged for 2 min. The samples were washed three times with phosphate-buffered saline and incubated in lysis buffer that contained 150 mm NaCl, 50 mM sodium phosphate (pH 7.2), 2 mM EDTA, 1 mM dithiothreitol, 10 mg/ml aprotinin, 0.2 mg/ml leupeptin, 0.5% SDS, 1% sodium deoxycholate, 1% Triton X-100, 5 mM NaF, 2 mM Na 4 P 2 O 7 , and 2 mM Na 3 VO 4 . The cell lysate was boiled for 5 min and incubated on ice for 1 h. The supernatant was precleared by incubation with 40 l of protein A-Sepharose for 6 h at 4°C and incubated overnight with G␣ i-1 , G␣ i-2 , G␣ i-3 , or G␣ o antibody at a final concentration of 4 g/ml, and then with 40 l of Protein A-Sepharose for another 1 h. The immunoprecipitates were collected, washed five times with 1 ml of wash buffer (0.5% Triton X-100, 150 mM NaCl, 10 mM Tris ⅐ HCl, pH 7.4), extracted with Laemmli buffer, boiled for 5 min, and separated by 12% SDS-PAGE. After transfer to nitrocellulose membranes, 32 P-labeled G proteins were visualized by autoradiography, and radioactivity was measured and expressed as cpm.
Agonist-stimulated G protein activity. Agonist-stimulated G protein activity was measured as previously described (23, 26, 34) . Membranes were obtained from control muscle cells, and cells were treated for 10 min with PMA (1 M). The membranes were incubated at 37°C with 60 nM [ 35 S]GTP␥S alone or with somatostatin (1 M) or DPDPE (1 M) in a medium containing 10 mM HEPES (pH 7.4), 100 M EDTA, and 10 mM MgCl 2 . After the reaction was stopped, the solubilized membranes were placed in wells precoated with specific antibodies to G␣ i-1 or G␣ i-2 . After 2 h, the wells were washed with phosphate buffer that contained 0.05% Tween 20, and the radioactivity was counted.
Radioligand binding. Radioligand binding to dispersed smooth muscle cells was measured as described previously (23) . Muscle cells were suspended in HEPES medium containing 1% bovine serum albumin (BSA). For competitive binding, triplicate aliquots (0.5 ml) of cell suspension (10 6 /ml) were incubated for 15 min with 50 pM [
125 I]somatostatin-14 alone or in the presence of unlabeled somatostatin-14 (10 M). Saturable [ 125 I]somatostatin binding was examined with the use of radioligand concentrations in the range of 10-400 pM in the presence or absence of unlabeled somatostatin (10 M). Bound and free radioligand were separated by rapid filtration under reduced pressure through 5-m polycarbonate Nucleopore filters followed by repeated washing (4 times) with 3 ml of ice-cold HEPES medium that contained 0.2% BSA. Nonspecific binding was measured as the amount of radioactivity associated with the muscle cells in the presence of 10 M of unlabeled ligand. Specific binding was calculated as the difference between total and nonspecific binding (24 Ϯ 6%).
Materials 
RESULTS

Selective phosphorylation of G␣ i-1 and G␣ i-2 by PKC.
The ability of PMA to induce phosphorylation of inhibitory G proteins (G␣ i-1 , G␣ i-2 , G␣ i-3 , and G␣ o ) was examined in dispersed intestinal smooth muscle cells labeled with 32 P i . Treatment of the cells with PMA (1 M) for 10 min caused a significant increase in phosphorylation of G␣ i-1 (178 Ϯ 10% above basal; P Ͻ 0.001) and G␣ i-2 (181 Ϯ 11%; P Ͻ 0.001), but not G␣ i-3 or G␣ o (Fig. 1) . The increase in phosphorylation of G␣ i-1 and G␣ i-2 was time and concentration dependent and was abolished by calphostin C (Figs. 1 and 2 ). Experiments in which muscle cells were treated with PMA followed by immunoprecipitation with phosphotyrosine antibodies and Western blot with G␣ i-1 and G␣ i-2 antibodies (n ϭ 3), or immunoprecipitation with G␣ i-1 and G␣ i-2 antibodies and Western blot with phosphotyrosine antibodies (n ϭ 3), did not disclose any evidence of tyrosine phosphorylation, implying that PKC phosphorylation of G␣ i-1 and G␣ i-2 was direct and did not involve tyrosine phosphorylation.
A similar pattern of selective phosphorylation of G␣ i-1 and G␣ i-2 , but not G␣ i-3 or G␣ o , was observed after a 10-min treatment of smooth muscle cells with cholecystokinin octapeptide (CCK-8; 1 nM), which ac- Intestinal smooth muscle cells labeled with 32 P were incubated with phorbol 12-myristate 13-acetate (PMA; 1 M, top) or cholecystokinin octapeptide (CCK-8; 1 nM, bottom) for 10 min in the presence (hatched bars) or absence (solid bars) of calphostin C (Cal. C). G␣ proteins were immunoprecipitated and subjected to SDS-PAGE. 32 P-labeled G␣ proteins were identified by autoradiography, and the measured radioactivity was expressed as counts per minute (cpm). PMA and CCK induced significant increases in phosphorylation of G␣ i-1 and G␣ i-2 , but not G␣ i-3 or G␣ o ; the increase was abolished by calphostin C. Values are means Ϯ SE of 4 experiments. 
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tivates G q/11 and stimulates phosphoinositide hydrolysis and PKC activity (25, 31) (Fig. 1) . CCK-induced phosphorylation of G␣ i-1 and G␣ i-2 was inhibited by calphostin C and by myristoylated pseudosubstrate peptide inhibitors of various PKC isozymes, including Ca 2ϩ -dependent PKC␣ and Ca 2ϩ -independent PKCε; a selective inhibitor of PKC␦ had no effect on phosphorylation of either G protein (Fig. 3) . The effects of PKC␣ and PKCε inhibitors were additive.
Treatment of the muscle cells with the phosphatases 1/2A inhibitor, calyculin A (10 M), also caused a time-dependent increase in phosphorylation of G␣ i-1 (211 Ϯ 26%) and G␣ i-2 (216 Ϯ 14%) that was maximal within 5 min (Fig. 4) . Calyculin-induced phosphorylation was abolished by bisindolylmaleimide (1 M), a competitive inhibitor of the ATP-binding site of PKC.
Blockade by PMA of agonist-stimulated activation of G i-1 and G i-2 . The effect of pretreatment with PMA on activation of G i-1 by somatostatin and G i-2 by DPDPE was determined in solubilized smooth muscle membranes. As previously shown (23, 26) , somatostatin and DPDPE increased the binding of [ 35 S]GTP␥S to 32 P-labeled G␣ i-1 and G␣ i-2 were identified by autoradiography, and the measured radioactivity was expressed as cpm. Values are means Ϯ SE of 3 experiments. **P Ͻ 0.01 inhibition of calyculin-induced phosphorylation.
G␣ i-1 and G␣ i-2 , respectively. Pretreatment of the cells for 10 min with PMA (1 M) before membrane isolation inhibited the increase in [
35 S]GTP␥S binding to G␣ i-1 and G␣ i-2 induced by the corresponding agonists (Fig.  5) .
Blockade by PMA of G␣ i-1 -and G␣ i-2 -mediated inhibition of adenylyl cyclase. To determine whether phosphorylation was associated with a decrease in signaling by G i-1 and G i-2 , smooth muscle cells were treated with PMA for 10 min and then with forskolin (10 M (Fig. 6 ). Pretreatment of the cells with PMA (1 M) had no significant effect on basal (4.4 Ϯ 0.6 pmol/10 6 cells) or forskolinstimulated (21.3 Ϯ 1.7 pmol/10 6 cells) cAMP levels, but it partially reversed the inhibition induced by DPDPE to 33 Ϯ 5% (P Ͻ 0.01 from control inhibition) and somatostatin to 43 Ϯ 7% (P Ͻ 0.01) without affecting inhibition induced by either CPA or acetylcholine (Fig.  6 ). The effect of PMA was suppressed by calphostin C (1 M) (Fig. 6) . Pretreatment with the inactive phorbol ester, 4␣-phorbol, had no significant effect on inhibition of forskolin-stimulated cAMP induced by all four ligands (76 Ϯ 2% to 82 Ϯ 2% inhibition). The reversal of cAMP inhibition mediated by G i-1 and G i-2 paralleled the selective phosphorylation of these two G proteins by PKC. It is worth noting that reversal of cAMP inhibition was partial, reflecting the fact that G o , which partly mediates the effects of somatostatin and opioid peptides, was not subject to phosphorylation by PKC.
The measurements were repeated in dispersed smooth muscle cells derived from muscle strips incubated for 24 h with 0.1 M PMA to downregulate PKC. The prolonged treatment with PMA did not affect basal (5.0 Ϯ 0.4 pmol/10 6 cells) or forskolin-stimulated (23.2 Ϯ 1.5 pmol/10 6 cells) cAMP levels, or the inhibition of cAMP induced by DPDPE or somatostatin. Treatment of these cells with 1 M PMA for 10 min did not reverse the inhibition of cAMP induced by DPDPE (81 Ϯ 4%) or somatostatin (76 Ϯ 3%), providing further support for the notion that blockade of cAMP inhibition was mediated by PKC (Fig. 7) .
Control studies were done to determine whether other protein targets (e.g., receptor or adenylyl cyclase) in the signaling pathway besides G i-1 and G i-2 were affected by PKC. Treatment with PMA had no effect on forskolin-stimulated adenylyl cyclase activity in smooth muscle membranes (Fig. 8) , or as noted above, on basal and forskolin-stimulated cAMP levels in dispersed smooth muscle cells, consistent with the notion that adenylyl cyclase types V/VI expressed in gastrointestinal smooth muscle and directly activated by forskolin is not inhibited by PKC (27) . However, adenylyl cyclase activity stimulated by GTP (1 mM) in membranes, which reflected net activation via G s and inhibition via G i /G o , was significantly augmented (72 Ϯ 4%; P Ͻ 0.001) by pretreatment of the cells with PMA, consistent with selective inactivation of one or more inhibitory G proteins by PKC (Fig. 8) . Similar results were obtained on treatment of muscle cells with pertussis toxin (200 ng/ml for 60 min; GTP alone: 7.5 Ϯ 0.5 pmol cAMP ⅐ mg protein Ϫ1 ⅐ min Ϫ1 ; GTP after pertussis toxin treatment: 14.0 Ϯ 1.4 pmol cAMP⅐mg protein Ϫ1 ⅐ min Ϫ1 ). Finally, 10-min treatment with PMA (1 M) had no direct effect on saturation or competitive somatostatin binding to somatostatin receptors on dispersed smooth muscle cells (Fig. 9) . A fit of the data to a two-site model yielded dissociation constant ( inhibition) and somatostatin to 37 Ϯ 8% (P Ͻ 0.01) without affecting inhibition induced by either CPA or acetylcholine (Fig. 6 ). The effect of CCK was suppressed by calphostin C and by myristoylated pseudosubstrate peptide inhibitors of PKC␣ and PKCε, but not PKC␦ (Figs. 6 and 10) (47) . The effectiveness of these inhibitors paralleled their ability to block CCKinduced phosphorylation of G␣ i-1 and G␣ i-2 (Fig. 3) . The role of PKC in reversing the inhibition of cAMP mediated by G i-1 and G i-2 was corroborated by studies with calyculin A. Pretreatment of muscle cells with 10 M calyculin A for 10 min partially reversed the inhibition of forskolin-stimulated cAMP induced by DPDPE to 34 Ϯ 3% (P Ͻ 0.01 from control inhibition) and somatostatin to 45 Ϯ 5%, but not that induced by CPA or acetylcholine (Fig. 11) . The effect of calyculin A was suppressed by bisindolylmaleimide, which blocks the catalytic site of PKC, but not by calphostin C, which blocks the regulatory diacylglycerol-binding site (Fig. 11) .
Inhibition of G i-1 -and G i-2 -mediated phospholipase C-␤ activity by PKC. The studies described above disclosed the role of PKC in attenuating inhibition of adenylyl cyclase activity mediated by the ␣-subunits of G i-1 and G i-2 . We next examined whether G protein phosphorylation by PKC attenuated the ability of the ␤␥-subunits of both G proteins to activate phospholipase C-␤3 (PLC-␤3). Our previous studies had shown that the ␤␥-subunits of G i-1 , G i-2 , and G i-3 selectively activated PLC-␤3 in smooth muscle (23) (24) (25) (26) . DPDPE caused a significant increase in PLC-␤ activity (746 Ϯ 29 cpm/10 6 cells [ 3 H]inositol phosphates). The PLC-␤ response was inhibited by 39 Ϯ 7% after activation of PKC by pretreatment of the cells for 10 min with acetylcholine; the inhibition was completely reversed by calphostin C. Similar inhibition of the PLC-␤ response to DPDPE was observed after stimulation of PKC activity with CCK-8 (46 Ϯ 8%), substance P (35 Ϯ 7%), and CPA (33 Ϯ 8%).
cANP-(4-23), a selective agonist of the natriuretic peptide clearance receptor, NPR-C, was recently shown to activate PLC-␤3 via the ␤␥-subunits of G i-1 and G i-2 (32, 33) . Pretreatment of the cells for 10 min with cANP-(4-23) (1 M) inhibited the PLC-␤ response to both DPDPE and somatostatin by 61 Ϯ 6% and 64 Ϯ 7%, respectively; the inhibition was partially reversed by calphostin C to 33 Ϯ 4% and 29 Ϯ 3%, respectively (P Ͻ 0.01 from control inhibition), implying that it was only partly mediated by PKC (Fig. 12) . In contrast, the PLC-␤ response to CPA was not affected by pretreatment of the cells with cANP-(4-23). The lack of effect of PKC on a response mediated by G i-3 is consistent with the lack of PKC-dependent phosphorylation of this G protein.
DISCUSSION
This study demonstrates that PKC-dependent phosphorylation of the ␣-subunits of G i-1 and G i-2 in smooth muscle limits the ability of the G proteins to transduce signals. PKC-dependent phosphorylation was confined to G i-1 and G i-2 and was not observed with G i-3 or G o . Selective phosphorylation of G␣ i-1 and G␣ i-2 resulted in heterologous desensitization of responses mediated by these two G proteins and could contribute to homologous desensitization.
Previous studies had shown that PKC was capable of phosphorylating G␣ i-2 in some cells only; phosphorylation of G s or G q/11 was not detected, and phosphorylation of G i-3 and G o was not examined (4-6, 22, 40, 45) . The present study showed that G i-1 and G i-2 , but not G i-3 or G o , were directly phosphorylated by PKC in smooth muscle and not via tyrosine kinase(s).
The role of PKC-dependent phosphorylation in heterologous desensitization of response was demonstrated in this study by activation of PKC with a phorbol ester (PMA) or an agonist (CCK-8), followed by treatment of the cells with agonists (somatostatin, DPDPE, CPA, and acetylcholine) known to activate specific G proteins. Pretreatment of muscle cells with PMA or CCK-8 caused rapid phosphorylation of G␣ i-1 and G␣ i-2 , but not G␣ o or G␣ i-3 , and reversed the inhibition of adenylyl cyclase mediated by somatostatin receptors that couple to G i-1 and G o (23) and opioid ␦-receptors that couple to G i-2 and G o (26), but not muscarinic M 2 and adenosine A 1 receptors that couple to G i-3 (24, 27) . Reversal of the inhibition induced by somatostatin and DPDPE was not complete, reflecting phosphorylation of G␣ i-1 and G␣ i-2 , but not G␣ o . Suppression of dephosphorylation with calyculin A increased phosphorylation of G␣ i-1 and G␣ i-2 but not G␣ i-3 ; the increase in phosphorylation of G␣ i-1 and G␣ i-2 was inhibited by bisindolylmaleimide, which blocks the ATP-binding site of PKC, implying that phosphorylation was mediated by receptor-independent, endogenous PKC activity normally contained by endogenous phosphatase activity.
In vitro studies on isolated ␣-subunits of various G proteins have shown that G␣ 12 , a ubiquitous G protein, and G␣ Z , which is predominantly expressed in platelets and neurons, are readily phosphorylated by PKC (11, 16, 19, 20) . The functional consequences of phosphorylation were alluded to but were not examined in situ. The primary sites of G␣ Z and G␣ 12 phosphorylation (Ser 27 and Ser 16 ) are located in the NH 2 -terminal domain of G␣ that determines the binding of ␣-and ␤␥-subunits; phosphorylation of these residues impedes the reassociation of ␣-and ␤␥-subunits (11, 16, 20) . Ser 16 in G␣ i-1 and G␣ i-2 is analogous to Ser 16 in G␣ Z and Ser 38 in G␣ 12 ; its phosphorylation might, therefore, be expected to impede reassociation of ␣-and ␤␥-subunits (11, 16) . Furthermore, the rate of GTP/ GDP exchange in G i-1 and G i-2 is more rapid than in G 12 and G Z . This makes it possible for PKC, whether activated by a phorbol ester or an agonist, to phosphorylate dissociated ␣-subunits, impede the reassociation of ␣-and ␤␥-subunits, and reduce the availability of the trimeric species for subsequent activation by other receptors, thereby leading to heterologous desensitization of responses mediated by a specific G protein. As shown in Fig. 5 , treatment with PMA decreased the ability of somatostatin and DPDPE to activate G i-1 and G i-2 , respectively, reflecting a decrease in the availability of the trimeric species.
The decrease in the availability of G proteins that results from phosphorylation of G␣ i-1 and G␣ i-2 also led to a decrease in responses mediated by ␤␥-subunits. The notion was tested with the NPR-C agonist, cANP-(4-23), which selectively activates G i-1 and G i-2 and stimulates PLC-␤3 activity via the ␤␥-subunits of both G proteins (32, 33) . Treatment of smooth muscle with cANP-(4-23) inhibited the PLC-␤ response to subsequent activation of G i-1 by somatostatin or activation of G i-2 by DPDPE. The PLC-␤ response was only partly restored when PKC activity was blocked with calphostin C. We postulate that residual inhibition reflects sequestration of G␣ i-1 and G␣ i-2 by binding to caveolin-3 (8, 17, 29) . In contrast, inhibition of the PLC-␤ response to DPDPE after treatment of muscle cells with acetylcholine (that activates G q/11 and G i-3 via M 3 and M 2 receptors, respectively) could be fully restored by calphostin C, because under these conditions, phosphorylation but not caveolin sequestration of G␣ i-1 and G␣ i-2 would be induced.
No evidence was obtained to suggest that other protein targets in the signaling pathways initiated by somatostatin or DPDPE (e.g., receptors or effector enzymes) were affected by PKC. Adenylyl cyclase type V/VI expressed in gastrointestinal smooth muscle is not a PKC substrate (27, 41) , and its activity was not affected by pretreatment with PMA or agonists. However, GTP-stimulated adenylyl cyclase activity, which reflected the balance of activation via G s and inhibition via G i /G o , was significantly augmented by PKC consistent with selective inactivation or reduction in the availability of G i-1 and G i-2 . Although PKC-dependent phosphorylation of somatostatin and opioid receptors has been reported in some cells (14, 43) , no effect was detected on the affinity or density of somatostatin receptors after treatment of muscle cells with PMA. Where the phosphoinositide pathway was concerned, prior activation of PKC inhibited PLC-␤3 activity stimulated by somatostatin-3 and opioid ␦-receptors coupled to G␤␥ i-1 and G␤␥ i-2 (23, 26 , and this study), but had no effect on PLC-␤3 activity stimulated by A 1 and M 2 receptors coupled to G␤␥ i-3 (24, 27, 29) . The pattern implied that inhibition of PLC-␤ activity by PKC in smooth muscle was G protein specific and was not exerted directly on PLC-␤ isozymes. This is in contrast to other cell types, where PKC was shown to inhibit directly mammalian or avian PLC-␤ isozymes (12, 39) .
The results leave open the question of whether phosphorylation by PKC could additionally target RGS proteins and enhance or attenuate their ability to accelerate GTP hydrolysis. Inhibition of response that results from acceleration of GTP hydrolysis by a cognate, phosphorylated RGS may not be readily distinguishable from inhibition that results from phosphorylation of the corresponding G protein.
PKC-dependent, G protein-specific heterologous desensitization could occur physiologically when neurotransmitters are delivered sequentially to target smooth muscle cells. During peristalsis, neurotransmitters (e.g., acetylcholine and tachykinins) that activate PKC could influence the response to other neurotransmitters, such as opioid peptide, which activates G i-2 , and vasoactive intestinal peptide, which activates G s via VPAC 2 receptors (42), and G i-1 and G i-2 via NPR-C (33).
